Skip to main content
Fig. 6 | Biomarker Research

Fig. 6

From: ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade

Fig. 6

ICOS DNA methylation status and mRNA expression is associated with survival and predictive for ICB response in melanoma. Overall survival in the TCGA melanoma cohort stratified according to (A) ICOS DNA methylation level at CpG 4/5 and (D) ICOS mRNA expression. To preclude a prognostic bias due to ICB administration, all patients who received anti-PD-1 or anti-CTLA-4 (N = 23) ICB were excluded from analysis. B ICOS mRNA expression is predictive of ICB therapy response and (C) associated with a prolonged PFS after ICB therapy initiation (Liu et al. cohort; N = 121; [26]). E ICOS DNA methylation levels at CpG sites 4/5 predicts ICB treatment response and (F) is associated with prolonged progression-free survival (PFS) following ICB treatment initiation (UHB ICB case/control set; N = 48). G High ICOS CpG 4/5 methylation is associated with adverse overall survival in the UHB ICB cohort (N = 123). P values refer to log-rank tests, t test, and ANOVA, respectively. Bars represent mean values

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us